Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
US-2016376348-A1 · Dec 29, 2016 · US
US10870692B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10870692-B2 |
| Application number | US-201916265437-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 1, 2019 |
| Priority date | Aug 2, 2006 |
| Publication date | Dec 22, 2020 |
| Grant date | Dec 22, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
Opening claim text (preview).
What is claimed is: 1. A purified multimer comprising a plurality of soluble, monoclonal antigen specific polypeptides, wherein each antigen specific polypeptide comprises a. a N-terminal leucine rich repeat (LRRNT), b. one or more internal leucine rich repeats (LRRs), c. a C-terminal leucine rich repeat (LRCCT), and d. a connecting peptide, wherein the connecting peptide comprises an alpha helix. 2. The multimer of claim 1 , comprising up to ten antigen specific polypeptides. 3. The multimer of claim 1 , wherein the antigen specific polypeptides bind a target protein. 4. The multimer of claim 1 , wherein the antigen specific polypeptides bind a target carbohydrate. 5. The multimer of claim 1 , wherein the antigen specific polypeptides bind a target pathogen. 6. The multimer of claim 2 , wherein the multimer is a multivalent multimer that binds to more than one target.
Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title
Orthomyxoviridae (F), e.g. influenza virus · CPC title
Bacillus (G) · CPC title
Specific host cells or culture conditions, e.g. components, pH or temperature · CPC title
for HIV · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.